MX2022000841A - Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias. - Google Patents

Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias.

Info

Publication number
MX2022000841A
MX2022000841A MX2022000841A MX2022000841A MX2022000841A MX 2022000841 A MX2022000841 A MX 2022000841A MX 2022000841 A MX2022000841 A MX 2022000841A MX 2022000841 A MX2022000841 A MX 2022000841A MX 2022000841 A MX2022000841 A MX 2022000841A
Authority
MX
Mexico
Prior art keywords
tmem16a
modulators
treatment
pyridine derivatives
respiratory conditions
Prior art date
Application number
MX2022000841A
Other languages
English (en)
Spanish (es)
Inventor
Jonathan David Hargrave
Thomas Beauregard Schofield
Christopher Stimson
Stephen Collingwood
Craig Buxton
Peter Ingram
Abdul Shaikh
Original Assignee
Tmem16A Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1910607.9A external-priority patent/GB201910607D0/en
Priority claimed from GBGB2005739.4A external-priority patent/GB202005739D0/en
Application filed by Tmem16A Ltd filed Critical Tmem16A Ltd
Publication of MX2022000841A publication Critical patent/MX2022000841A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
MX2022000841A 2019-07-24 2020-07-24 Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias. MX2022000841A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1910607.9A GB201910607D0 (en) 2019-07-24 2019-07-24 Compounds
GBGB2005739.4A GB202005739D0 (en) 2020-04-20 2020-04-20 Compounds
PCT/GB2020/051778 WO2021014166A1 (en) 2019-07-24 2020-07-24 Pyridine derivatives as tmem16a modulators for use in the treatment of respiratory conditions

Publications (1)

Publication Number Publication Date
MX2022000841A true MX2022000841A (es) 2022-06-08

Family

ID=71948615

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000841A MX2022000841A (es) 2019-07-24 2020-07-24 Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias.

Country Status (16)

Country Link
US (1) US20220235006A1 (cg-RX-API-DMAC10.html)
EP (1) EP4003516A1 (cg-RX-API-DMAC10.html)
JP (1) JP7583022B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220063162A (cg-RX-API-DMAC10.html)
CN (1) CN114616226B (cg-RX-API-DMAC10.html)
AU (1) AU2020317036A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022001164A2 (cg-RX-API-DMAC10.html)
CA (1) CA3145120A1 (cg-RX-API-DMAC10.html)
CL (1) CL2022000147A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022002022A2 (cg-RX-API-DMAC10.html)
CR (1) CR20220072A (cg-RX-API-DMAC10.html)
IL (1) IL290035A (cg-RX-API-DMAC10.html)
MX (1) MX2022000841A (cg-RX-API-DMAC10.html)
PE (1) PE20221441A1 (cg-RX-API-DMAC10.html)
PH (1) PH12022550181A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021014166A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4003516A1 (en) * 2019-07-24 2022-06-01 Tmem16A Limited Pyridine derivatives as tmem16a modulators for use in the treatment of respiratory conditions
KR20260025059A (ko) * 2024-08-13 2026-02-23 전남대학교산학협력단 신규한 치환된 피리딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 호흡기 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042524A1 (en) 2003-10-30 2005-05-12 Virochem Pharma Inc. Pyridine carboxamide and methods for inhibiting hiv integrase
EP3612180B1 (en) 2017-04-17 2023-10-11 The Regents of the University of California Substituted 2-acylamino-cycloalkylthiophene-3-carboxylic acid arylamides as inhibitors of calcium-activated chloride channel tmem16a
GB201801355D0 (en) * 2018-01-26 2018-03-14 Enterprise Therapeutics Ltd Compounds
EP4003516A1 (en) * 2019-07-24 2022-06-01 Tmem16A Limited Pyridine derivatives as tmem16a modulators for use in the treatment of respiratory conditions

Also Published As

Publication number Publication date
CN114616226A (zh) 2022-06-10
BR112022001164A2 (pt) 2022-03-15
IL290035A (en) 2022-03-01
WO2021014166A1 (en) 2021-01-28
US20220235006A1 (en) 2022-07-28
JP2022541311A (ja) 2022-09-22
AU2020317036A1 (en) 2022-03-17
KR20220063162A (ko) 2022-05-17
CO2022002022A2 (es) 2022-06-10
PE20221441A1 (es) 2022-09-21
CN114616226B (zh) 2025-03-04
CA3145120A1 (en) 2021-01-28
CR20220072A (es) 2022-06-29
PH12022550181A1 (en) 2023-01-16
EP4003516A1 (en) 2022-06-01
JP7583022B2 (ja) 2024-11-13
CL2022000147A1 (es) 2022-10-07

Similar Documents

Publication Publication Date Title
CO2020010552A2 (es) Compuestos
ECSP20021913A (es) Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso
CL2022000093A1 (es) Imidazopirimidinas como inhibidores de eed y uso de estas
CO2020002959A2 (es) Moduladores de piruvato quinasas y uso de los mismos
CY1124022T1 (el) Σχημα χορηγησης για νιτροκατεχολες
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
CO2019006622A2 (es) Derivados de pirazol como inhibidores de malt1
UY37900A (es) Nuevos derivados de rapamicina
UY37124A (es) Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos
UY37435A (es) Pirrolidinas sustituidas y métodos para usarlas
CR20170118A (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
CL2025001073A1 (es) Preparación de aminas de heteroaril-bifenilo
MX387596B (es) Degradadores selectivos del receptor de estrógeno y sus usos.
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
UY33817A (es) ?nuevas oxindolpirimidinas bencílicas?.
UY36077A (es) Derivados de 6-amino-8h-pteridin-7-ona como moduladores de ror gamma y composiciones farmacéuticas que los contienen
CY1111758T1 (el) Τρικυκλικες ενωσεις και χρηση αυτων ως ρυθμιστες υποδοχεα γλυκοκορτικοειδους
NI201500081A (es) Derivados de imidazopiridazina como moduladores del receptor gabaa
CR20150378A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
MX372772B (es) Enonas piridazolilo y pirimidinilo tricíclicas sustituidas con arilo y arilalquilo como moduladores de la inflamación antioxidantes.
MX2021002215A (es) Derivados de tetrahidropiridopirimidina como moduladores de ahr.
MX2019005934A (es) Compuestos de benzodiazolio como inhibidores del canal de sodio epitelial (enac).
ECSP17010238A (es) Compuestos novedosos de pirimidina sustituidos
CL2017002498A1 (es) Piridopirimidinonas y su uso como modulares del receptor nmda